Atherectomy Device Market (By Devices Type: Atherectomy Devices, Angioplasty Balloon Catheters, Stents, Intravascular Ultrasound Catheters, Optical Coherence Tomography Catheters, Drug-Coated Balloons, Embolic Protection Devices, Thrombectomy Devices, Aortic Stent Grafts, Endovascular Grafts, Laser Atherectomy Devices, Orbital Atherectomy Systems, and Others; By Application; By End-user) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033


The global atherectomy devices market size surpassed USD 765.49 million in 2023 and is estimated to hit around USD 1,512.89 million by 2033, growing at a CAGR of 7.05% from 2024 to 2033.

The market is driven by atherectomy device innovations that include technological advancements, such as miniaturization and improved imaging modalities, enhancing precision and efficacy in plaque removal.

Atherectomy Devices Market Size 2024 to 2033

Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare

 

Key Takeaways

  • North America led the market with the biggest market share of 45% in 2023.
  • Asia Pacific is projected to expand at the fastest rate during the forecast period of 2024-2033.
  • By device type, the drug-coated balloons (DCBs) segment held the largest share of the market in 2023.
  • By device type, the intravascular ultrasound (IVUS) catheter segment is expected to show the fastest growth.
  • By application type, the peripheral artery disease segment held the dominating share of the market in 2023.
  • By application type, the coronary artery disease segment represents another highly influential segment for the forecast period.
  • By end-user, the cardiac catheterization labs segment held the dominating share of the market in 2023.
  • By end-user, the interventional radiology departments segment is expected to witness a significant rate of expansion during the forecast period.

Atherectomy Devices Market in the U.S. 2024 to 2033

The U.S. atherectomy devices market size was valued at USD 241.13 million in 2023 and is anticipated to reach around USD 476.56 million by 2033, poised to grow at a CAGR of 7.10% from 2024 to 2033.

U.S. Atherectomy Devices Market Size 2024 to 2033

North America led the global market with the highest market share of 45% in 2023. Atherectomy devices have seen significant utilization and dominance in North America, particularly in the United States of America (USA) and Canada. The USA boasts advanced healthcare infrastructure and extensive research and development capabilities, driving the adoption of atherectomy devices for the treatment of atherosclerosis. Similarly, Canada benefits from a well-established healthcare system and a high prevalence of cardiovascular diseases, contributing to the widespread use of these devices.

Atherectomy Devices Market Share, By Region, 2023 (%)

Asia-Pacific is expected to witness growth at a significant rate in the atherectomy devices market during the forecast period of 2024-2033. Asia Pacific region is experiencing rapid growth and emergence as a key market for atherectomy devices. Countries like China, India, Japan, and South Korea are witnessing increasing adoption of these devices due to rising healthcare awareness, improving access to advanced medical technologies, and a growing burden of cardiovascular diseases. As healthcare infrastructure continues to develop and awareness of minimally invasive treatment options expands, the Asia Pacific region is expected to play a significant role in the global market for atherectomy devices.

Atherectomy Devices Market Overview

Atherectomy devices are specialized medical instruments used to remove plaque buildup from arteries, particularly in the treatment of atherosclerosis. Atherosclerosis is a condition where plaque, made up of cholesterol, fat, calcium, and other substances, accumulates on the inner walls of arteries, leading to narrowing and hardening of the arteries. Atherectomy procedures are minimally invasive alternatives to traditional surgical methods, such as bypass surgery, and are often performed to restore blood flow in arteries affected by atherosclerosis.

There are several types of devices, each designed for specific applications and preferences of clinicians. Rotational devices use a rotating burr or blade to shave away plaque from the artery walls, while directional devices employ a cutting mechanism to remove plaque in a controlled manner. Laser atherectomy devices use laser energy to vaporize plaque, and orbital atherectomy devices utilize a unique orbital mechanism to sand down plaque. Each type of device has its advantages and may be chosen based on factors such as the location and severity of plaque buildup and the patient’s overall health condition.

Growth Factors

Atherectomy devices have benefited from continuous technological advancements, leading to the development of more efficient and precise tools for plaque removal in arteries. Innovations such as improved rotational mechanisms, enhanced visualization capabilities, and miniaturization of devices have contributed to greater efficacy and safety in atherectomy procedures. These advancements enable physicians to navigate through complex arterial structures with increased precision, facilitating thorough plaque removal while minimizing damage to surrounding tissues.

The growth of the atherectomy devices market is bolstered by ongoing clinical research and evidence supporting their effectiveness and safety in treating arterial disease. Clinical trials and studies provide valuable insights into the outcomes and benefits of atherectomy procedures, helping to establish their role in the management of various arterial conditions. As more evidence emerges demonstrating favorable patient outcomes and reduced procedural complications, confidence in the use of atherectomy devices among healthcare providers grows, driving further adoption and utilization.

Comprehensive physician training and education programs play a crucial role in the adoption and utilization of atherectomy devices. Manufacturers invest in training initiatives to educate healthcare professionals on the proper use of atherectomy systems, procedural techniques, and patient selection criteria. By equipping physicians with the necessary knowledge and skills, these training programs empower them to confidently incorporate atherectomy into their clinical practice, expanding access to this minimally invasive treatment option for patients with arterial disease.

The atherectomy devices market continues to evolve with expanded indications and applications, allowing for their utilization in a broader range of clinical scenarios. Manufacturers continually seek regulatory approvals for new indications and expand the capabilities of existing devices to address evolving clinical needs. This expansion of indications, coupled with advancements in device design and technology, enhances the versatility and effectiveness of atherectomy procedures, positioning them as a valuable treatment option for an increasing number of patients with arterial disease.

Atherectomy Devices Market Scope

Report Coverage Details
Growth Rate from 2024 to 2033 CAGR of 7.05%
Global Market Size in 2023 USD 765.49 Million
Global Market Size by 2033 USD 1,512.89 Million
U.S. Market Size in 2023 USD 241.13 Million
U.S. Market Size by 2033 USD 476.56 Million
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Devices Type, By Application, and By End-user
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa


Atherectomy Devices Market Dynamics

Drivers

Technological innovation

Advancements in medical technology have revolutionized the atherectomy devices market. Miniaturization, improved imaging modalities, and the development of novel materials have enabled the creation of increasingly sophisticated atherectomy devices. For example, the integration of advanced imaging techniques such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT) allows for real-time visualization of arterial structures, guiding precise interventions.

The miniaturization of devices has facilitated the use of minimally invasive procedures, reducing patient discomfort and recovery time. Continued innovation in device design, including the incorporation of robotics and artificial intelligence, holds promise for further enhancing the efficacy and safety of the products and services of the atherectomy devices market.

Deeper understanding of arterial biomechanics

Atherosclerosis is not merely a passive buildup of plaque within arteries but a dynamic process influenced by arterial biomechanics. Research into the mechanical forces acting on arterial walls, such as shear stress and cyclic strain, has revealed their profound effects on endothelial function, plaque development, and vulnerability. This deeper understanding has informed the design of atherosclerosis devices that not only remove plaque but also modulate biomechanical factors to promote arterial healing and stability.

Devices capable of delivering localized drug therapies or modulating blood flow patterns can help prevent restenosis and thrombosis. By integrating biomechanical principles into device design and treatment strategies, clinicians can tailor interventions to address the specific biomechanical challenges posed by individual patients’ arterial lesions, leading to improved outcomes in atherosclerosis management.

  • In April 2022, AngioDynamics unveiled the Auryon Atherectomy System, a groundbreaking laser atherectomy system designed to treat any lesion type, length, and location with minimal impact on vessel walls. This innovative technology marks a significant advancement in atherectomy procedures, offering clinicians greater flexibility and precision in treating atherosclerosis.

Restraint

Regulatory hurdles in navigating complex approval processes and safety standards for atherosclerosis devices

Navigating the complex landscape of regulatory approvals poses a significant restraint in the development and deployment of atherosclerosis devices. Manufacturers must adhere to stringent safety standards and demonstrate the efficacy of their devices through rigorous clinical trials, adding time and cost to the development process. Regulatory agencies, such as the FDA in the United States and the European Medicines Agency (EMA) in Europe, require comprehensive data on device performance, including safety profiles and long-term outcomes, before granting market approval.

Additionally, evolving regulatory requirements and guidelines further compound the challenge, necessitating continuous adaptation and compliance. Delays in regulatory approvals or failure to meet stringent criteria can significantly impede the availability of new atherosclerosis devices, limiting options for patients and clinicians and hindering advancements in treatment modalities for arterial disease.

Opportunities

Emerging therapeutic modalities on expanding treatment options for atherosclerosis management

One significant opportunity in the atherectomy devices market lies in the exploration and development of emerging therapeutic modalities. Beyond traditional atherectomy procedures, researchers are investigating innovative approaches such as gene therapy, targeted drug delivery, and immunomodulation to address the underlying mechanisms of arterial disease.

Gene therapy holds promise for delivering therapeutic genes directly to affected arteries, promoting plaque stabilization and regression. Similarly, targeted drug delivery systems enable precise delivery of therapeutic agents to diseased arterial segments, minimizing systemic side effects and enhancing efficacy. Furthermore, immunomodulatory strategies aim to modulate the immune response within arterial walls, reducing inflammation and promoting plaque stability. By leveraging these emerging therapeutic modalities, atherosclerosis devices can offer more tailored and effective treatments, potentially improving outcomes for patients with arterial disease.

  • In January 2024, Researchers at Ludwig Maximilian University (LMU) Christian Weber and Yvonne Döring unveiled a novel signaling pathway implicated in inflammatory cardiovascular diseases, shedding new light on the pathogenesis of atherosclerosis.

Integration of digital health technologies on enhancing monitoring and personalized management of atherosclerosis

Another critical aspect of the atherectomy devices market is patient engagement and self-management, which can be enhanced through interactive educational resources, real-time feedback, and support networks, empowering individuals to take an active role in managing their arterial health. Overall, the integration of digital health technologies into atherosclerosis devices holds promise for improving patient outcomes, enhancing clinical decision-making, and reducing healthcare costs.

Another critical aspect of the atherectomy devices market is patient engagement, and self-management that can be enhanced through interactive educational resources, real-time feedback, and support networks, empowering individuals to take an active role in managing their arterial health. Overall, the integration of digital health technologies into atherosclerosis devices holds promise for improving patient outcomes, enhancing clinical decision-making, and reducing healthcare costs.

  • In November 2023, the Centro Nacional de Investigaciones Cardiovasculares (CNIC), in collaboration with Santander Bank, conducted the PESA-CNIC-Santander Study, focusing on early subclinical atherosclerosis progression. The comprehensive study underscores the importance of aggressive risk management from a young age to prevent or reverse the development of atherosclerosis, highlighting the critical role of proactive healthcare interventions.

Devices Type Insights

The drug-coated balloons (DCBs) segment dominated the atherectomy devices market with the largest share in 2023. DCBs Catheters. DCBs have gained popularity due to their ability to deliver anti-proliferative drugs directly to the arterial wall during balloon angioplasty, reducing restenosis rates and the need for additional stents.

The intravascular ultrasound (IVUS) catheter segment is expected to show the fastest growth in the atherectomy devices market during the forecast period. IVUS catheters provide real-time, high-resolution imaging of the arterial lumen and vessel wall, aiding in lesion assessment, stent sizing, and optimization of stent deployment. Both technologies have contributed to improved procedural outcomes, reduced complication rates, and enhanced patient care in the management of atherosclerotic disease.

Application Insights

The peripheral artery disease (PAD) treatment devices segment dominated the atherectomy devices market in 2023. Recent advancements in PAD treatment devices have focused on enhancing efficacy and durability while minimizing invasiveness. Technologies such as drug-coated balloons and drug-eluting stents have shown promising results in reducing restenosis rates and improving the long-term patency of treated arteries. Additionally, the development of atherectomy devices with improved navigation and tissue removal capabilities has expanded treatment options for complex PAD lesions, particularly in cases where traditional angioplasty or stenting may not be feasible.

The coronary artery disease (CAD) intervention device segment shows notable growth in the atherectomy devices market during the forecast period. In the realm of CAD intervention devices, there has been a noteworthy emphasis on enhancing precision and safety during percutaneous coronary interventions (PCIs). Innovations such as bioresorbable vascular scaffolds (BVS) and drug-eluting stents with biocompatible coatings aim to reduce the risk of late stent thrombosis and improve vascular healing. Furthermore, the integration of intravascular imaging technologies, such as optical coherence tomography (OCT) and intravascular ultrasound (IVUS), has enabled more accurate lesion assessment and optimized stent placement, leading to improved procedural outcomes and long-term clinical success rates.

End User Insights

The catheterization labs and interventional radiology departments segment dominated the atherectomy devices market in 2023. cardiac catheterization labs and interventional radiology departments have seen increased usage of atherosclerosis devices. Cardiac catheterization labs specialize in diagnosing and treating cardiovascular conditions, including atherosclerosis, through minimally invasive procedures.

The interventional radiology department segment is expected to witness a significant rate of expansion during the forecast period. Interventional radiology departments offer expertise in image-guided interventions, making them well-suited for atherosclerosis device placement and monitoring. Both settings provide advanced equipment and skilled personnel, facilitating the precise placement and monitoring of atherosclerosis devices to manage arterial disease effectively. This trend reflects the growing importance of minimally invasive techniques and interdisciplinary collaboration in the treatment of atherosclerosis.

Recent Developments

  • In October 2023, Cardio Flow, Inc., announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its FreedomFlow® Orbital Atherectomy Peripheral Platform.
  • In September 2023, Avinger Inc., a commercial-stage medical device company, announced the full commercial launch of its Tigereye® ST next-generation image-guided chronic total occlusion (CTO) crossing system.

Atherectomy Devices Market Companies

  • Abbott Laboratories
  • Boston Scientific Corporation
  • BD
  • Cardinal Health Inc.
  • Koninklijke Philips NV
  • Medtronic Plc
  • Terumo Corporation
  • Avinger
  • Cardiovascular Systems
  • Ra Medical Systems

Segments Covered in the Report

By Devices Type

  • Atherectomy Devices
  • Angioplasty Balloon Catheters
  • Stents (Bare-Metal, Drug-Eluting, Bioresorbable)
  • Intravascular Ultrasound (IVUS) Catheters
  • Optical Coherence Tomography (OCT) Catheters
  • Drug-Coated Balloons
  • Embolic Protection Devices
  • Thrombectomy Devices
  • Aortic Stent Grafts
  • Endovascular Grafts
  • Laser Atherectomy Devices
  • Orbital Atherectomy Systems
  • Rotational Atherectomy Devices
  • Directional Atherectomy Devices
  • Chronic Total Occlusion (CTO) Devices

By Application

  • Peripheral Artery Disease (PAD) Treatment Devices
  • Coronary Artery Disease (CAD) Intervention Devices
  • Carotid Artery Disease Intervention Devices
  • Renal Artery Disease Intervention Devices
  • Aortic Atherosclerosis Intervention Devices

By End-user

  • Cardiac Catheterization Labs
  • Interventional Radiology Departments
  • Vascular Surgery Centers
  • Cardiology Clinics
  • Academic Research Institutions

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Frequently Asked Questions

How big is the atherectomy devices industry?
The global atherectomy devices market size is expected to increase USD 1,512.89 million by 2033 from USD 765.49 million in 2023.
What is the growth rate of the atherectomy devices industry?
The global atherectomy devices market will register growth rate of 7.05% between 2024 and 2033.
Who are the prominent players operating in the atherectomy devices market?
The major players operating in the atherectomy devices market are Abbott Laboratories, Boston Scientific Corporation, BD, Cardinal Health Inc., Koninklijke Philips NV, Medtronic Plc, Terumo Corporation, Avinger, Cardiovascular Systems, Ra Medical Systems, and Others.
Which are the driving factors of the atherectomy devices market?
The driving factors of the atherectomy devices market are the advancements in medical technology and deeper understanding of arterial biomechanics.
Which region will lead the global atherectomy devices market?
North America region will lead the global atherectomy devices market during the forecast period 2024 to 2033.

PROCEED TO BUY :

   USD 5400
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

Get a Sample